U.S. markets open in 9 hours 24 minutes
  • S&P Futures

    4,159.25
    -5.50 (-0.13%)
     
  • Dow Futures

    33,982.00
    -34.00 (-0.10%)
     
  • Nasdaq Futures

    13,902.75
    -16.50 (-0.12%)
     
  • Russell 2000 Futures

    2,229.20
    -9.20 (-0.41%)
     
  • Crude Oil

    61.06
    -0.29 (-0.47%)
     
  • Gold

    1,793.90
    +0.80 (+0.04%)
     
  • Silver

    26.58
    +0.01 (+0.06%)
     
  • EUR/USD

    1.2044
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3933
    +0.0001 (+0.01%)
     
  • USD/JPY

    108.0000
    -0.0430 (-0.04%)
     
  • BTC-USD

    54,028.39
    -2,055.45 (-3.66%)
     
  • CMC Crypto 200

    1,245.07
    -17.89 (-1.42%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,058.42
    +549.87 (+1.93%)
     

Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results

  • Oops!
    Something went wrong.
    Please try again later.
Constellation Pharmaceuticals , Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth quarter 2020 results and provide a business update. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 6971724.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contacts

Kia Khaleghpour, PhD
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com